Published in Blood Weekly, June 11th, 2009
"Studies regarding mantle cell lymphoma (MCL) as a secondary synchronous or metachronous malignancy are limited. Here we report a patient who received concurrent chemoradiotherapy for his advanced sigmoid adenocarcinoma and developed MCL in the duodenal bulb 20 months later," wrote M.T. Liao and colleagues.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.